Optimizing limbic selective D2/D3 receptor occupancy by risperidone:: A[123I]-epidepride SPET study

Selective action at limbic cortical dopamine D2-like receptors is a putative mechanism of atypical antipsychotic efficacy with few extrapyramidal side effects. Although risperidone is an atypical antipsychotic with high affinity for D-2 receptors, low-dose risperidone treatment is effective without inducing extrapyramidal symptoms. The objective was to test the hypothesis that treatment with low-dose risperidone results in limbic selective' D-2/D-3 receptor blockade in vivo. Dynamic single photon emission tomography (SPET) sequences were obtained over 5 hours after injection of [I-123]-epidepride (similar to150 MBq), using a high-resolution triple-headed brain scanner (Marconi Prism 3000XP). Kinetic modelling was performed using the simplified reference region model to obtain binding potential values. Estimates of receptor occupancy were made relative to a normal volunteer control group (n = 5). Six patients treated with low-dose risperidone (mean = 2.6 mg) showed moderate levels of D-2/D-3 occupancy in striatum (49.9%), but higher levels of D-2/D-3 occupancy in thalamus (70.8%) and temporal cortex (75.2%). Occupancy values in striatum were significantly different from thalamus (F (1,4) = 26.3, p < 0.01) and from temporal cortex (F (1,4) = 53.4, p < 0.01). This is the first study to evaluate striatal and extrastriatal occupancy of risperidone. Low dose treatment with risperidone achieves a similar selectivity of limbic cortical over striatal D-2/D-3 receptor blockade to that of atypical antipsychotics with lower D-2/D-3 affinity such as clozapine, olanzapine and queLiapine. This finding is consistent with the relevance of 'limbic selective' D-2/D-3 receptor occupancy to the therapeutic efficacy of atypical antipsychotic drugs.